Apellis Pharmaceuticals, Inc. (APLS)
Largest Insider Buys in Sector
APLS Stock Price History Chart
APLS Stock Performance
About Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases. It also develops EMPAVELI (systemic pegcetacoplan) for the treatment …
Insider Activity of Apellis Pharmaceuticals, Inc.
Over the last 12 months, insiders at Apellis Pharmaceuticals, Inc. have bought $0 and sold $49.93M worth of Apellis Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Apellis Pharmaceuticals, Inc. have bought $30.16M and sold $37.22M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 500,000 shares for transaction amount of $20M was made by Morningside Venture Investments Ltd (10 percent owner) on 2021‑11‑18.
List of Insider Buy and Sell Transactions, Apellis Pharmaceuticals, Inc.
| 2024-09-16 | Sale | director | 37,000 0.0303% | $36.23 | $1.34M | -22.94% | ||
| 2024-09-16 | Sale | VP/Chief Accounting Officer | 192 0.0002% | $36.21 | $6,952 | -22.94% | ||
| 2024-09-03 | Sale | VP/Chief Accounting Officer | 550 0.0005% | $39.49 | $21,720 | -26.60% | ||
| 2024-06-21 | Sale | director | 37,000 0.028% | $39.24 | $1.45M | -6.41% | ||
| 2024-05-08 | Sale | Chief Scientific Officer | 78,907 0.0651% | $42.35 | $3.34M | -9.74% | ||
| 2024-04-08 | Sale | Chief Scientific Officer | 69,107 0.0577% | $54.17 | $3.74M | -27.00% | ||
| 2024-04-01 | Sale | Chief Financial Officer | 4,000 0.0033% | $58.66 | $234,640 | -33.77% | ||
| 2024-03-19 | Sale | director | 18,681 0.0156% | $57.18 | $1.07M | -30.10% | ||
| 2024-03-18 | Sale | Chief Business & Strat Officer | 9,913 0.0083% | $56.90 | $564,050 | -29.23% | ||
| 2024-03-15 | Sale | VP/Chief Accounting Officer | 184 0.0002% | $56.46 | $10,389 | -29.85% | ||
| 2024-03-13 | Sale | Chief Technical Officer | 11,220 0.0094% | $57.56 | $645,838 | -30.55% | ||
| 2024-03-08 | Sale | Chief Scientific Officer | 69,107 0.0574% | $62.19 | $4.3M | -35.15% | ||
| 2024-03-01 | Sale | Chief Executive Officer | 250,000 0.2068% | $64.11 | $16.03M | -37.24% | ||
| 2024-03-01 | Sale | Chief Financial Officer | 6,000 0.0049% | $63.22 | $379,340 | -37.24% | ||
| 2024-02-12 | Sale | Chief Scientific Officer | 1,148 0.001% | $67.77 | $77,796 | -40.06% | ||
| 2024-02-12 | Sale | Chief Executive Officer | 3,962 0.0034% | $67.77 | $268,492 | -40.06% | ||
| 2024-02-12 | Sale | General Counsel | 781 0.0007% | $67.77 | $52,926 | -40.06% | ||
| 2024-02-12 | Sale | Chief Financial Officer | 1,431 0.0012% | $67.77 | $96,974 | -40.06% | ||
| 2024-02-12 | Sale | Chief Commercial Officer | 1,148 0.001% | $67.77 | $77,796 | -40.06% | ||
| 2024-02-12 | Sale | Chief Business & Strat Officer | 597 0.0005% | $67.77 | $40,457 | -40.06% |
Insider Historical Profitability
| Sullivan Timothy Eugene | Chief Financial Officer | 93338 0.075% | $27.85 | 1 | 10 | +1.94% |
| SCHEIBLER LUKAS | Chief Research Officer | 68299 0.0549% | $27.85 | 1 | 12 | <0.0001% |
| Morningside Venture Investments Ltd | 10 percent owner | 12806342 10.2951% | $27.85 | 9 | 0 | +6.91% |
| venBio Global Strategic Fund II L.P. | 10 percent owner | 3579305 2.8774% | $27.85 | 1 | 0 | +31.35% |
| Hillhouse Capital Management, Ltd. | 10 percent owner | 3527152 2.8355% | $27.85 | 1 | 0 | +31.35% |
Institutional Investor Ownership
| Wellington Management Company | $885.11M | 12.41 | 15.06M | -8.44% | -$81.54M | 0.15 | |
| Ecor1 Capital Llc | $667.59M | 9.36 | 11.36M | +1.65% | +$10.84M | 4.68 | |
| Avoro Capital Advisors Llc | $653.11M | 9.15 | 11.11M | 0% | +$0 | 7.83 | |
| The Vanguard Group | $558.75M | 7.83 | 9.51M | -0.52% | -$2.93M | 0.01 | |
| BlackRock | $322.97M | 4.53 | 5.49M | +2.11% | +$6.66M | 0.01 |